Efficacy and Safety Study of ESBA1008 Versus EYLEA®
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of ESBA1008 versus EYLEA® in
the treatment of exudative age-related macular degeneration.